Microscopic colitis: A review of etiology, treatment and refractory disease

Table 2 Summary of studies demonstrating efficacy of budesonide for treating microscopic colitis

	Number of patients	Mean age (yr)	Treatment	Remission rate1	Relapse rate2
Miehlke et al[31], 2008	48	57.5	Budesonide 9 mg/d for 6 wk, followed by budesonide 6 mg/d vs placebo for 6 mo	Short-term 96%	26% vs 65% placebo, P = 0.022
				Long-term 74% vs 35% placebo, P = 0.008
Bonderup et al[19], 2009	34	62.8	Budesonide 9 mg/d for 6 wk, followed by budesonide 6 mg/d vs placebo for 24 wk	Long-term	53%
				76.5% vs 12% placebo, P < 0.001
Miehlke et al[15], 2014	92	58.8	Budesonide 9 mg/d vs placebo for 8 wk	At 8 wk,	35%
				80% vs 59.5% placebo, P = 0.072
Münch et al[16], 2014	92	56.7	Budesonide 9 mg/d for 8 wk, followed by budesonide 4.5 mg/d vs placebo for 6 mo	Short-term 84.5%	82.1% vs 12.5% placebo
				Long-term
				61.4% vs 16.7% placebo, P < 0.001

¹Short-term remission rate is within 6 wk during induction phase. Long-term remission rate is at 6 mo of maintenance therapy, unless otherwise specified;

²After discontinuation of therapy.